80 Guest Street
5th Floor
Boston, MA 02135
United States
617 500 8864
https://www.aurabiosciences.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 88
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Elisabet de los Pinos Ph.D. | Founder, CEO, President & Director | 895,16k | S.O. | 1974 |
Ms. Julie B. Feder | Chief Financial Officer | 604,2k | S.O. | 1971 |
Dr. Mark Plavsic D.V.M., Ph.D. | Chief Technology Officer | S.O. | S.O. | 1961 |
Mr. Conor Kilroy | General Counsel & Secretary | S.O. | S.O. | 1982 |
Mr. Patrick Nealon | Senior Vice President of Clinical Development Operations | S.O. | S.O. | S.O. |
Dr. Bruce Brown M.D. | Senior VP & Therapeutic Area Head of Urologic Oncology | S.O. | S.O. | S.O. |
Dr. Anthony Daniels M.D. | Therapeutic Area Head of Ocular Oncology | S.O. | S.O. | S.O. |
Dr. Richard Mountfield Ph.D. | Senior Vice President of Regulatory Affairs & Quality | S.O. | S.O. | S.O. |
Dr. Jill J. Hopkins M.D. | Chief Medical Officer & President of Research and Development | S.O. | S.O. | 1965 |
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
L’ISS Governance QualityScore de Aura Biosciences, Inc. en date du 29 juin 2024 est 7. Les scores principaux sont Audit : 7; Société : 7; Droits des actionnaires : 8; Compensation : 7.